BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 10, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aranesp darbepoetin alfa: Phase III started

Amgen partner Kyowa began Japanese Phase III testing of darbepoetin alfa to treat anemia. Amgen markets darbepoetin alfa as Aranesp the Americas,...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >